Q BioMed Inc., a commercial stage biotech company, and its technology research partner Mannin Research Inc., presented positive data on a potential new treatment for acute kidney injury (AKI).   
There is a significant opportunity to advance a therapeutic solution to treat AK and address a patient population that contributes to 20% of all hospitalizations in the U.S.  Current treatments for AKI are mainly supportive and do not treat the underlying condition.

Mannin’s chief scientific officer, Dr. Susan Quaggin, presented data that showed that the Ang-Tie2 signaling pathway is a promising therapeutic target to prevent AKI after ischemia caused by ischemia–reperfusion (IR) injury to the kidney.  Ischemia in the kidney occurs in a range of clinically important scenarios such as hypotension, sepsis, and cardiovascular events such as strokes.

“We are very encouraged by this data. Taken together with our recently announced funding and establishment of a research center in Saxony, Germany, this data will enable us to advance our program in developing therapeutics to treat acute kidney injury, bolstering our pipeline,” said Dr. Nikopoulos. “We look forward to the day when we can make a difference in the lives of patients with kidney and cardiovascular diseases.”

Q BioMed and Mannin have been partners since 2015 and Q BioMed has an exclusive option on all Mannin portfolio assets.